ERRATA

The November 1, 2008, article by Marcucci et al entitled, “Prognostic Significance of, and Gene and MicroRNA Expression Signatures Associated With, *CEBPA* Mutations in Cytogenetically Normal Acute Myeloid Leukemia With High-Risk Molecular Features: A Cancer and Leukemia Group B Study” (J Clin Oncol 26:5078-5087, 2008) contained errors.

In Figure 1B, the *P* value was given as $P = .001$, whereas it should have been $P < .001$.

In the References section, reference no. 11 was given as:

5. Langer C, Radmacher MD, Ruppert AS, et al: High *FLT3* expression associates with other molecular prognostic markers, poor outcome and a distinct gene-expression signature in cytogenetically normal patients younger than 60 years with acute myeloid leukemia: A Cancer and Leukemia Group B (CALGB) study. Blood 111:5371-5379, 2008

While it should have been:

5. Langer C, Radmacher MD, Ruppert AS, et al: High *BAALC* expression associates with other molecular prognostic markers, poor outcome and a distinct gene-expression signature in cytogenetically normal patients younger than 60 years with acute myeloid leukemia: A Cancer and Leukemia Group B (CALGB) study. Blood 111:5371-5379, 2008

DOI: 10.1200/JCO.2008.21.0476

The September 1, 2008, correspondence by Thariat et al entitled, “Cetuximab Pharmacokinetics in End-Stage Kidney Disease Under Hemodialysis” (J Clin Oncol 26:4223-4225, 2008) contained an error.

The last sentence of the first paragraph indicated that Cetuximab was instituted at a dose of 250 mg/kg weekly, whereas it should have been 250 mg/m² weekly, as follows:

“Cetuximab was instituted at a dose of 250 mg/m² weekly for a 55-year-old patient with head and neck cancer.”

The online version has been corrected in departure from the print.

DOI: 10.1200/JCO.2008.21.0468